Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Obstructive sleep apnea and diabetes: a state of the art review.Chest. 2017; 152: 1070-1086
- Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association.Circulation. 2021; 144: e56-e67
- Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies.Int J Cardiol. 2013; 169: 207-214
- Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.Sleep Breath. 2022;
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME Trial.Diabetes Care. 2020; 43: 3007-3015